Group 1 - The company Duorui Pharmaceutical announced an earnings forecast on January 29, expecting a net loss attributable to shareholders of 76.24 million to 99.12 million yuan for 2025, compared to a net loss of 62.67 million yuan in the same period last year [1] - The primary reason for the earnings change is the significant decline in sales volume and price of its main product, sodium acetate Ringer's injection, which will be subject to the 10th batch of national centralized drug procurement starting from April 2025 [1] - The company's subsidiary, Sichuan Duorui, completed an acquisition in November 2024, which will be included in the consolidated financial statements, leading to steady business progress and revenue growth in 2025, although it will not cover R&D and financial expenses, resulting in continued losses [1] Group 2 - The investigation into the "Jie Wo Rui" redemption crisis on the Shuibei Gold platform revealed a 40-fold leverage bet, indicating that the platform incurs losses as gold prices rise [1] - Investors reported that the proposed redemption plan offered only 20% of the principal, which they found unacceptable [1]
多瑞医药：预计2025年度净利润亏损7624.49万元~9911.83万元